Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023

EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced results from all three (3) Phase 1 studies evaluating its self-amplifying mRNA (samRNA) vaccine candidates against COVID-19 (part of the company’s CORAL program) are to be presented at IDWeek 2023, occurring October 11-15, 2023, in Boston, MA. Last week, Gritstone bio announced a contract with the Biomedical Advanced Research and Development Authority (BARDA) to advance the program into a 10,000 patient, randomized Phase 2b comparative study against COVID-19. The agreement was awarded as part of ‘Project NextGen,’ an initiative by the U.S. Department of Health and Human Services (HHS) to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19.

Gritstone last presented data from the CORAL-BOOST and CORAL-CEPI studies in April 2023 (press release). At IDWeek, Gritstone will present further follow up from both of those studies. Additionally, representatives from the Infectious Diseases Clinical Research Consortium (IDCRC), a clinical trials network established by the National Institute of Allergy and Infectious Disease (NIAID), will present the first results from the CORAL-NIH study, a Phase 1 study conducted by IDCRC and supported by NIAID (and the third and final Phase 1 study from the CORAL program).

CORAL-CEPI and CORAL-BOOST presentations (presented by Gritstone):

• Abstract 1538194 (Poster Presentation): Preliminary evidence of durable immune responses induced by self-amplifying mRNA (samRNA) vaccine candidates against SARS-CoV-2 in vaccine-naive South African population (CORAL-CEPI study)
  Date/Time: Saturday, Oct 14, 2023, 12:15 - 1:30 PM
  Poster #: 2372
  Presenter: Atul Nagare, MD
  Location: BCEC Poster Hall

• Abstract 1530224 (Poster Presentation): Preliminary results of durable immune response induced by a self-amplifying mRNA (samRNA) SARS-CoV-2 vaccine candidate, GRT-R910, in adults previously vaccinated with mRNA or AZD1222 primary series (CORAL-BOOST study)
  Date/Time: Saturday, Oct 14, 2023, 12:15 - 1:30 PM
  Poster #: 2346
  Presenter: Meghan G. Hart
  Location: BCEC Poster Hall

CORAL-NIH presentation (presented by IDCRC):

• Abstract 1530224 (Poster Presentation): An Interim Report of the Safety, Reactogenicity, and Immunogenicity of a Self-amplifying mRNA (samRNA) COVID-19 Vaccine GRT-R910 as a Booster in Healthy Adults